Skip to main content

Table 1 Baseline characteristics

From: Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017

 201520162017
Patients795878047709
Deaths138114124
Patients, excl. Deaths782076907585
 OATOAT + AMbOATOAT + AMbOATOAT + AMb
No. (%)No. (%)No. (%)No. (%)No. (%)No. (%)
Dispensed ADHD medication274 (3.5)312 (4.1)349 (4.6)
Age
  ≤ 25171 (2.2)5 (1.8)135 (1.8)7 (2.2)120 (1.6)9 (2.6)
 26–351551 (19.8)81 (29.6)1403 (18.2)90 (28.8)1333 (17.6)84 (24.1)
 36–452605 (33.3)107 (39.1)2508 (32.6)118 (37.8)2392 (31.5)134 (38.4)
 46–552544 (32.5)69 (25.2)2540 (33.0)79 (25.3)2548 (33.6)97 (27.8)
  ≥ 56949 (12.1)12 (4.4)1104 (14.4)18 (5.8)1192 (15.7)25 (7.2)
Mean (SD)43.9 (9.7)41.0 (8.5)44.5 (9.8)40.8 (8.7)45.0 (9.9)41.8 (9.0)
Gender
 Male5430 (69.4)193 (70.4)5354 (69.6)221 (70.8)5245 (69.1)254 (72.8)
 Female2390 (30.6)81 (29.6)2336 (30.4)91 (29.2)2340 (30.9)92 (26.4)
OAT opioidsa
 Methadone (included levomethadone)3216 (41.1)72 (26.3)3066 (39.9)74 (23.7)2981 (39.3)92 (26.4)
 Buprenorphine (included combinations)4604 (58.9)202 (73.7)4624 (60.1)238 (76.3)4604 (60.7)257 (73.6)
  1. ADHD Attention deficit hyperactivity disorder, AM ADHD medication (atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and methylphenidate), NorPD Norwegian Prescription Database, SD standard deviation, and No Number of patients
  2. a The last dispensed OAT opioid in the calendar year
  3. b On all medical indications
  4. The table displays the baseline characteristics of patients who were dispensed at least one OAT opioid per year in the period from 2015 to 2017